Hosted on MSN
Talphera outlines accelerated NEPHRO enrollment and lowers 2025 cash operating expense guidance amid protocol shift
Vincent J. Angotti, CEO, highlighted “the progress made this past quarter, specifically in the acceleration of the NEPHRO study enrollment” and detailed the impact of restructuring efforts, stating ...
Thank you for your interest in writing for Nature Protocols. These guidelines are intended to help you at all stages, from deciding whether to accept an invitation to write for Nature Protocols, to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results